Loading
When a company stops developing a cancer drug for business rather than safety reasons and leaves it idle for two years, it would be obliged to offer the rights, data package and remaining drug supply to qualified non-profit or academic developers on pre-set terms, keeping the right to resume. This turns the stalled-asset registry's listing into a duty.
A legal or funder-imposed condition (for example on drugs that received public research funding, orphan designation or tax credits) that oncology assets discontinued for non-safety reasons and not actively developed for two years must be offered for licence to qualified non-profit or academic developers on pre-set terms (non-exclusive for research, exclusive for defined rare indications, modest royalties on commercialisation). Data packages and remaining drug supply are included. Companies retain rights to resume. This complements the stalled-asset registry by creating a duty, not just a listing.
Shares A repurposing label pathway with short exclusivity that non-profits can hold, A non-profit pharmaceutical company for the cancers markets ignore.
Shares Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement, Secrecy and intellectual property block collaboration.
Shares Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement, Secrecy and intellectual property block collaboration.
Shares A non-profit pharmaceutical company for the cancers markets ignore, The valley of death between lab and product, Rare and paediatric cancers without markets.
Shares Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement, Secrecy and intellectual property block collaboration.
Shares Secrecy and intellectual property block collaboration, The valley of death between lab and product, Rare and paediatric cancers without markets.
Shares Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement, Secrecy and intellectual property block collaboration.
Shares A non-profit pharmaceutical company for the cancers markets ignore, The valley of death between lab and product.